iiinova — where your digital self keeps evolving

Reposted by Gomis

IRB Barcelona @irbbarcelona.org · 12/03/2025

🧪Don't miss this webinar by Dr. @rgergom.bsky.social (#IRBBarcelona-#Inbiomotion) that explores the biology & mechanism of action of the MAF gene, shedding light on its significant impact on patient outcomes. @sourcebioscience.bsky.social youtu.be/M7bvPjPQCq0?feature=shared #BreastCancer

youtu.be

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

072

Reposted by Gomis

IRB Barcelona @irbbarcelona.org · 24/02/2025

📌 MetEND: Descodificando las dependencias entre la #metástasis y la vasculatura. El proyecto coordinado por el Dr. @rgergom.bsky.social pretende desarrollar nuevas opciones para el tratamiento del #CáncerdeMama metastásico, para lo que estudiará la relación entre la metástasis y la vascularización.

141

Reposted by Gomis

IRB Barcelona @irbbarcelona.org · 30/01/2025

💬Mesa Redonda: Presente y Futuro del #CáncerDeMama 🗣️Dr. @rgergom.bsky.social (@irbbarcelona.org) 🗣️Dr. César Serrano (Hospital Vall d'Hebron-@vhio.bsky.social) 🗣️Carme Segura, paciente cáncer de mama 🎙️Modera: Michele Catanzaro 🗓️Miérc, 5 de febrero 🕡 18:30-20:00h 📍@iec.cat 🔗 bit.ly/3Wx0Fw5

021

Reposted by Gomis

Marcos Malumbres @mmalumbres.bsky.social · 27/11/2024

Exciting news in cancer therapy! The order of drugs impacts the duration of treatment, toxicity, and economic cost. A necessary example of how relevant academic, self-funded trials are!! Breast #cancer #oncosky #oncsky #medsky 🧪 @natureportfolio.bsky.social www.nature.com/articles/d41...

nature.com

Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use

No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.

15614

Reposted by Gomis

IRB Barcelona @irbbarcelona.org · 26/11/2024

🔵 The #IRBBarcelona Growth Control & #Cancer #Metastasis lab, led by @rgergom.bsky.social is offering two 3-year #PhD #fellowships in the framework of the Adaptmet Project for young scientists community who wish to undertake a doctoral degree in #biomedicine. Read more here ➡️ shorturl.at/MDX95

043

Gomis @rgergom.bsky.social · 18/11/2024

Terrific talk by @mmalumbres.bsky.social !! at the biomed conference in barcelona

041

Reposted by Gomis

Marcos Malumbres @mmalumbres.bsky.social · 18/11/2024

Let’s get started: BioMed Conference on “Mechanisms of resistance in cancer”. Francesc Posas, director of the IRB Barcelona, introducing the event! #oncosky 🧪

282

Reposted by Gomis

Marcos Malumbres @mmalumbres.bsky.social · 17/11/2024

Just one day left for the #BarcelonaBiomed Conference "Molecular Determinants of #Cancer Therapy Resistance"! 🗓️ 18-20 Nov, 2024 #Barcelona 🤝 Angel R Nebreda (#IRB), Clare Isake (ICR_London) & @mmalumbres.bsky.social (VHIO), with @batllelab.bsky.social and a long list of speakers. ➡️bit.ly/4dBTSYI

0269

Reposted by Gomis

Marcos Malumbres @mmalumbres.bsky.social · 15/11/2024

Cancer cell biologists in the 2024 meeting of the Spanish Association of Cancer Research (ASEICA) in beautiful Zaragoza.. waiting for you guys here in @bsky.app

181

Reposted by Gomis

Marcos Malumbres @mmalumbres.bsky.social · 15/11/2024

Historical alliance between Spanish associations against #cancer… ASEICA and AECC ContraCancer… we need you in @bsky.app

173